Sophisticated new home community near Nashville with assignment to sought-after Williamson County Schools is now open Sophisticated new home community near Nashville with assignment to sought-after Williamson County Schools is now open

Google Cloud revenue reached $13.6 billion in Q2 2025, up 32% year-over-year, with operating margin expanding from 11.3% to 20.7%. Proprietary TPU systems deliver 2x efficiency and 50% performance gains, enabling nine of the world's largest AI labs to run on Google Cloud. Q2 CapEx surged to $22.4 billion, with 2025 guidance raised to $85 billion, two-thirds directed to servers, compressing near-term free cash flow.

Largest ever in program history - 8 scholarships in 2025 and 38 since inception. Scholarship recipient's representative of communities across the Local Priority Area ("LPA").

Aptevo Therapeutics (NASDAQ:APVO) saw its shares jump sharply after the company reported encouraging clinical data from its Phase 1b/2 RAINIER trial evaluating mipletamig, a first-in-class CD123 x CD3 bispecific antibody, in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Aptevo said that Cohort 3 of the trial achieved a 100% remission rate, with 40% of patients reaching minimal residual disease (MRD)-negative status, a key indicator linked to improved long-term outcomes.

Lesaka Technologies, Inc. continues to deliver promising fundamental indicators, despite its underwhelming year-over-year stock performance. The firm's expansion in African consumer markets, robust earnings guidance, and insider buying support a long-term bullish outlook. Short-term risks include high CapEx, emerging market volatility, and delayed profitability consolidation, but current sales multiples appear attractive.

Holiday retail sales are set to rise up to 3.4%, with SN, GCO, CASY and SFM poised to benefit from resilient consumer spending.

Merck and Daiichi's raludotatug deruxtecan wins FDA Breakthrough tag for treating CDH6 expressing platinum-resistant ovarian, primary peritoneal or fallopian tube cancers.

Occidental Petroleum Corporation boosted production 14.8% YoY to 1.395 million BOE/day while keeping absolute operating costs unchanged. Per-barrel domestic lease operating costs fell to $8.55 in Q2-FY25, outperforming guidance and strengthening cost resilience. Structural savings delivered $500 million in reductions, including 13% lower unconventional well costs and faster Permian drilling cycles.

Rocket Lab USA Inc (NASDAQ:RKLB) (Nasdaq: RKLB) shares fell 10% to $48.48 in midday trading on Tuesday after the provider of launch services and space systems revealed in a Securities and Exchange Commission (SEC) filing that it has entered into a new at-the-market (ATM) equity offering arrangement under which it could raise up to $750 million by selling company shares from time to time. The offering replaces a previous $500 million agreement, under which $396.6 million of company shares were already sold.

KMB drives growth through innovation, premiumization and its Powering Care strategy focused on efficiency and consumer engagement.

Intel and Advanced Micro are racing ahead in AI chips, but AMD's growth outlook and strong positioning give it the investment edge.

GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.

NYT's 11.3M digital subscribers, rising ARPU and strong Q3 guidance highlight its digital-first revenue momentum.

With a fair chunk of the population now glued to TV screens on weekend afternoons, gaming titan DraftKings is looking to hit its stride, with the company regularly seeing surges in gaming and fantasy-related operations throughout the period.

NHTSA said it has nine reports of parents being unable to open doors on 2021 Tesla Model Y vehicles.

KIM gets an A- rating with a stable outlook, backed by strong operations, a solid balance sheet and a grocery-anchored portfolio.

dLocal (DLO) is a promising fintech company operating in emerging markets, offering a unique investment opportunity at an attractive valuation. After extensive analysis of DLO's financials, risks, and growth milestones, I am convinced of its quality and potential. DLO stands out as one of the few remaining quality fintech plays, making it a compelling choice for investors seeking growth.

DHR's Life Sciences unit faces revenue declines from weak demand, but new products and biotech advances offer growth potential.

Celsius Holdings surges 112.9% in 2025, powered by innovation, Alani Nu momentum and global expansion, underscoring its strong growth story.

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks are NIKE, AGCO, Docusign and InterDigital.